The recent approval of 90Y-labeled Zevalin (IDEC Pharmaceuticals Corp., San Diego, CA) for radioimmunotherapy of non-Hodgkin’s lymphoma has highlighted the regulatory requirement of patient-specific internal radiati - Ibritumomab tiuxetan - Document - PDFSEARCH.IO

First Page	Meta Content
	The recent approval of 90Y-labeled Zevalin (IDEC Pharmaceuticals Corp., San Diego, CA) for radioimmunotherapy of non-Hodgkin’s lymphoma has highlighted the regulatory requirement of patient-specific internal radiati Add to Reading List Document Date: 2005-10-18 14:16:03 Open Document File Size: 60,46 KB Share Result on Facebook City San Diego / Voxel / / Company LG / IDEC Pharmaceuticals Corp. / / IndustryTerm transport algorithms / quantitative imaging / pre-treatment whole body imaging / / MedicalCondition tumor / Refractory Non-Hodgkin’s Lymphoma / lymphoma / tumors / / MedicalTreatment radiotherapy / radioimmunotherapy / radiation / / Person Thomas SR / / Position medical physicist / Mp / / Product Zevalin / / ProvinceOrState Connecticut / / Technology radiopharmaceuticals / radiation / radiation transport algorithms / / SocialTag Radiation oncology Radioactivity Nuclear physics Ibritumomab tiuxetan Radiation therapy Radioimmunotherapy Absorbed dose Dosimetry Ionizing radiation Medicine

The recent approval of 90Y-labeled Zevalin (IDEC Pharmaceuticals Corp., San Diego, CA) for radioimmunotherapy of non-Hodgkin’s lymphoma has highlighted the regulatory requirement of patient-specific internal radiatiAdd to Reading List